Professor Robert Baxter

DSc, FAA
Professor
Medicine, Northern Clinical School
Kolling Institute of Medical Research

Telephone +61 2 9926 4730
Fax +61 2 9926 4034

Website Related website
Related website

Map

Biographical details

After 18 years as Director of the Kolling Institute of Medical Research at the University of Sydney/ Royal North Shore Hospital, Rob Baxter stepped down in January 2012 to continue his research on the biochemistry, cell biology, and endocrinology of the insulin-like growth factors and their binding proteins. He remains at the Kolling Institute where he heads the Hormones and Cancer Division.

His research has contributed to understanding both the regulation of normal tissue and body growth, and the aberrant cellular growth in cancer and overgrowth syndromes. His group’s achievements include characterising the protein complexes that carry IGFs in the circulation, and discovering how IGF binding proteins affect cancer growth and survival by modulating cell signalling pathways. His collaborative clinical studies have significantly advanced understanding of the role of these proteins in a variety of conditions including pregnancy, tumour-related hypoglycemia, and critical illness. He also heads the laboratory for Cellular and Diagnostic Proteomics in the Kolling Institute, and is involved in biomarker discovery studies in breast and pancreatic cancers, and growth disorders.

Rob has a PhD in Biochemistry from the University of Sydney, was awarded a DSc in 1990, and was elected a Fellow of the Australian Academy of Science in 2004. He has over 300 research publications, cited over 20,000 times, and an h-index of 75. He has been invited to give keynote plenary lectures in Australia, Asia, Europe, South America and the USA, and has received major research awards including the Dale Medal (Society for Endocrinology, UK), Wellcome (now GSK) Australia Medal, Lemberg Medal (ASBMB), Ramaciotti Medal for Excellence in Biomedical Research, and ICCNS-Springer Award (International). He was a member of NHMRC Research Committee from 1997-2003, chaired the National Committee for Biomedical Sciences of the Australian Academy of Science from 2006-2009, and is currently Vice-President of the International Society for IGF Research.

Selected grants

2015

  • Breast cancer therapies that target IGFBP-3 signalling; Baxter R, Boyle F, Martin J; Cancer Council New South Wales/Research Project Grants.

2014

  • How the repair of DNA damage is regulated by IGFBP-3, a protein at the crossroads between cell death and survival.; Baxter R; Australian Research Council (ARC)/Discovery Projects (DP).

2012

  • MALDI MS Imaging for Cancer Biomarker Discovery in the Northern Translational Cancer Research Unit; Baxter R; Cancer Institute New South Wales/Research Infrastructure Grant.
  • Data Linkage for NSW Bioresources using CHeReL; Baxter R, Robinson B, Boyle F, Clarke C, Marsh D; Cancer Institute New South Wales/Biobanking Stakeholder Network Funding.
  • Bruker Daltonics autoflex speed Maldi-tof/tof mass spectrometer, Biomarker identification and Maldi-Imaging solutions; Baxter R; DVC Research/Cancer Research Fund.
  • Regulation of Mesenchymal Stem Cell Differentiation; Baxter R; DVC Research/Bridging Support Grant.
  • Bruker Daltonics autoflex speed MALDI-TOF/TOF mass spectrometer; Baxter R, Halliday G, Marsh D, Gill A, Clarke S, Smith R, Little C, Jackson C, O'Neill C, Murphy C, Sharland A, Chadban S, Mason R, Assinder S, Verdurand M, Richardson D, Machaalani R, Hambly B, Chan-Ling T, Dos Remedios C, Holsinger D, Lay P; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • IncuCyte FLR Microscope System and Cell Incubator; Baxter R, Marsh D, Jackson C, O'Neill C, Ashton A, Howell V; Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Major Equipment.
  • Pyk2: a central mediator of gonadotropin action in ovarian cancer; Marsh D, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IncuCyte FLR Microscope System (Essen Bioscience); Marsh D, Baxter R, Morris J, Jackson C, Howell V; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Targetting IGFBP-3 signalling pathways as a novel therapeutic approach in triple negative breast cancer; Baxter R, Martin J; Cancer Council New South Wales/Research Project Grants.

2010

  • Facilities for cryogenic storage and transport of tissue bank materials; Clarke C, Baxter R, Lee C, Marsh D; Cancer Institute New South Wales/Equipment Grant.
  • In-Vivo Multispectral Imaging FX System: small animal imaging for multi-modal molecular signal localisation in live animals; Marsh D, Baxter R, Ashton A, Howell V, Soon P, Little D, Robinson B; Cancer Institute New South Wales/Equipment Grant.
  • Protein discovery for breast cancer diagnosis; Baxter R, Moore (Loveridge) K, Marsh D, Boyle F, McCarthy N; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Breast cancer biospecimen resource; Morey A, Forbes J, Scott R, Spigelman A, Clarke C, Kefford R, Baxter R, Marsh D, Friedlander M, Harnett P, Balleine R, Bilous M, Boyages J, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • MMI Smart Cut Plus laser microdissector; Baxter R, Little C, Marsh D, Keast J; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • Breast Cancer Tissue Bank - data collection and management infrasture; Clarke C, Scott R, Balleine R, Carpenter J, Baxter R, Bilous M, Lee S, Marsh D, Scott R, Spigelman A; Cancer Institute New South Wales/Infrastructure Grant.
  • SELDI Protein Chip Mass Spectrometer with SELDI Software and computer,; Baxter R; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Protein discovery for breast cancer diagnosis; Baxter R, Moore (Loveridge) K, Marsh D; DVC Research/Bridging Support Grant.
  • The role of microRNAs and EGFR in chemoresistance in breats cancer-associated fibroblasts; Soon P, Baxter R; DVC Research/Cancer Research Fund.
  • How IGFBP-3 improves cancer cell responsiveness to DNA-damaging therapies; Baxter R; Australian Research Council (ARC)/Discovery Projects (DP).

2008

  • Growth Research; Baxter R; North Sydney Central Coast Area Health Services (NSCCAH)/Research Grant.
  • Mechanisms of growth factor action in ovarian cancer; Baxter R, Zaman M, Zaman M; DVC Research/International Visiting Research Fellowship (IVRF).
  • Leica TCS SP5 Laser Scanning Confocal Microscope; Baxter R; Clive & Vera Ramaciotti Foundation/Research Grant.

2007

  • Interactions between hypoxia, inflammation and insulin-like growth factor (IGF) binding proteins (IGFBPs) in ovarian cancer; Baxter R; Cancer Institute New South Wales/International Collaboration Grant.
  • Breast Cancer Tissue Bank; Marsh D, Clarke C, Scott R, Kefford R, Balleine R, Baxter R, Bilous M, Carpenter J, Friedlander M, Forbes J, Boyages J, Spigelman A, Sutherland R, Harnett P, Morey A; National Breast Cancer Foundation/Research Grants.
  • Two-dimensional Gel Electrophoresis Equipment & Software; Baxter R; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Confocal microscope for cancer research in the Northern Hub; Baxter R, Robinson B; Cancer Institute New South Wales/Infrastructure Grant.
  • Tumour bank officer in the Northern Hub; Smith R, Marsh D, Baxter R, Robinson B; Cancer Institute New South Wales/Infrastructure Grant.
  • Proteolysis of binding protein complexes regulates IGF bioavailability; Firth S, Baxter R; Australian Research Council (ARC)/Discovery Projects (DP).
  • Proteomic screening for apoptotic markers in cancer; Baxter R, Leong S, Christopherson R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Novel regulators of fat cell differentiation; Twigg S, McLennan S, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Breast cancer biospecimen resource; Kefford R, Balleine R, Baxter R, Clarke C, Bilous M; National Breast Cancer Foundation/Facilitation Grant.

2006

  • Biomarkers of cell signalling pathways on ovarian cancer; Marsh D, Baxter R; Cancer Council New South Wales/Research Project Grants.
  • Wash System for Beckman 3000 Laboratory Automation System; Baxter R, Marsh D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • FAXSCalibur 4 -colour Flow Cytometer; Baxter R, Firth S, Marsh D, Schedlich L, Scott C, Martin J, Robinson B; Cancer Institute New South Wales/Research Grants Program - Category 2.
  • Development of an immunoassay for a novel serum biomarker of GH administration.; Baxter R; United States Anti-Doping Agency (USA)/United States Anti-Doping Agency (USADA) Research Grants Program.
  • University of Sydney - Bridging Support Grant; Baxter R; University of Sydney/Bridging Support.

2005

  • Igfbp-3 As A Growth Inhibitor In Breast Cancer; Baxter R, Firth S, Martin J; Worldwide Cancer Research/Research Grants Scheme.
  • Breast cancer biospecimen resource; Marsh D, Clarke C, Harnett P, Spigelman A, Forbes J, Harnett P, Friedlander M, Sutherland R, Boyages J, Morey A, Spigelman A, Scott R, Balleine R, Baxter R, Bilous M, Kefford R; Cancer Institute New South Wales/Research Grant.
  • Breast Cancer biospecimen resource; Boyages J, Spigelman A, Forbes J, Marsh D, Friedlander M, Morey A, Spigelman A, Sutherland R, Scott R, Balleine R, Baxter R, Bilous M, Kefford R, Clarke C; National Breast Cancer Foundation/Grant-in-Aid.
  • Investigation of the chemokine CXCL 1 as a biomarker of growth factor signalling in ovarian cancer; Marsh D, Baxter R; University of Sydney/Cancer Research Fund.
  • ProteomeX MS and personnel support for the new facuility; Baxter R, Christopherson R, Daly R, Guilhaus M, Kavallaris M, Clarke S, Molloy M, Baker M; Cancer Institute New South Wales/Research Support.
  • Automated Precision Liquid Handling System; Benn D, Chen X, Chung L, Baxter R, Marsh D, Robinson B, Firth S; University of Sydney/Research Support.
  • Wallac Ten Detector Gamma Counter; Baxter R; Clive & Vera Ramaciotti Foundation/General Grants.
  • Cancer functional genomics in the northern hub; Baxter R, Marsh D, Smith R; Cancer Institute New South Wales/Research Grant.
  • NSW Cancer Proteomics Research; Baxter R, Baker M; Cancer Institute New South Wales/Infrastructure Grant.

2004

  • Proteomic analysis of subcellular changes during apoptosis; Baxter R, Christopherson R; Australian Research Council (ARC)/Discovery Projects (DP).
  • Endocrine and autocrine regulation of breast cancer cell growth by IGF-binding protein-3; Martin J, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Role of IGF binding protein-3(IGFBP-3) and IGFBP-5 as modulators of nuclear hormone signalling; Schedlich L, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Breast cancer biospecimen resource; Clarke C, Balleine R, Bilous M, Kefford R, Baxter R, Harnett P, Spigelman A, Forbes J, Spigelman A, Marsh D, Boyages J, Friedlander M, Harnett P, Morey A, Scott R, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.
  • Proteomic analysis of molecules involved in the growth promoting effects of insulin-like growth factor binding protein-2; Baxter R; DVC Research/Research and Development Scheme: Research and Development (R&D).
  • Tumour tissue bank and arrayer; Baxter R; Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Major Equipment.

2003

  • Flexi-dry microprocessor controlled manifold freeze dryer; Baxter R, Firth S; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Detection of biomarkers of human growth hormone administration by SELDI-TOF mass spectrometry; Baxter R, Kazlauskas R, Ho K; Department of Communications, Information Technology & the Arts (CITA)/Research Grant.
  • SELDI Protein Chip System; Baxter R; Clive & Vera Ramaciotti Foundation/General Grants.
  • Defining interactions between anabolic and peptide hormones: requirements for a robust test for growth hormone doping; Ho K, Kazlauskas R, Baxter R, Irie M, Handelsman D; Department of Communications, Information Technology & the Arts (CITA)/Research Grant.
  • SELDI Protein Chip System; Baxter R, Christopherson R, King N; University of Sydney/Major Equipment.
  • Structural elucidation and functional analysis of insulin-like growth factor binding protein-3 domains; Baxter R, Firth S; Australian Research Council (ARC)/Discovery Projects (DP).

2002

  • Ultracentrifuge; Baxter R; University of Sydney/Major Equipment.
  • Defining interactions between anabolic and peptide hormones: requirements for a robust test for growth hormone doping; Ho K, Irie M, Kazlauskas R, Baxter R, Handelsman D; World anti-doping agency (Canada)/World Anti-Doping Agency Research Grants Program.
  • Beckman Optima XL-100K Ultracentrifuge; Firth S, Baxter R, Delhanty P; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Interactions between IGFBP-3 and TGFbeta in the inhibition of breast cancer cell growth; Firth S, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • Interactions between insulin-like growth factor binding protein-3 and transforming growth factor beta signalling in the inhibition of human breast cancer cell growth; Baxter R, Firth S; Cunningham Foundation/Research Project Grants.
  • Growth hormone research; Baxter R; Medicine Research/Medicine Grant Scheme.
  • Real-time thermal cycler; Baxter R; University of Sydney/Major Equipment.
  • Interactions between IGFBP-3 and transforming growth factor beta signalling in the inhibition of human breast cancer cell growth; Baxter R, Firth S; Leo and Jenny Leukaemia and Cancer Foundation/Cure Cancer Foundation.

2000

  • Research agreement The role of hepatic GH and insulin responsiveness in the regulation of endotoxin processing and sensitivity between Pharmacia & Upjohn AB and the University of Sydney; Van der Berghe G, Claes H, Fryklund L, Baxter R; Pharmacia & Upjohn Pty Ltd/BLO Project.
  • Nuclear import and actions of insulin-like growth factor binding protein-3 (IGFBP-3) and IGFBP-5; Schedlich L, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Regulation of the acid-labile subunit of the IGF binding protein complex by hepatic factors; Delhanty P, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Structure-function relationships in IGF binding protein (IGFBP)-3 and IGFBP-5 complexes; Baxter R, Firth S; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Insulin-like growth factor binding protein-3 (IGFBP-3) sensitivity and signalling in breast cancer; Martin J, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Role of insulin-like growth factor binding protein-3 as a mediator of apoptosis in human breast cancer; Butt A, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.
  • IGF-binding protein proteolysis: a regulator of cell proliferation; Martin J, Baxter R; National Health and Medical Research Council (NHMRC)/Project Grants.

1999

  • Fluorescent microscope for a laser scanning confocal system; Schedlich L, Baxter R; Clive & Vera Ramaciotti Foundation/Research Grants.

Selected publications

Download citations: PDF RTF Endnote

Edited Books

  • LeRoith, D., Zumkeller, W., Baxter, R. (2003). Insulin-like Growth Factor Receptor Signalling. United States: Springer.

Book Chapters

  • Baxter, R. (2008). Insulin-like Growth Factors and Tumor Hypoglycemia. In Ian D. Hay, John A. H. Wass (Eds.), Clinical Endocrine Oncology - 2nd Edition, (pp. 576-581). United Kingdom: Blackwell Publishers.
  • Baxter, R., Fanayan, S. (2003). Functional relationships between transforming growth factor-beta and the insulin-like growth factor binding proteins. In Leroith, Zimkeller, Baxter (Eds.), Insulin-Like Growth Factors, (pp. 281-293). New York: Springer.

Journals

  • Hoyos, C., Killick, R., Keenan, D., Baxter, R., Veldhuis, J., Liu, P. (2014). Continuous Positive Airway Pressure Increases Pulsatile Growth Hormone Secretion and Circulating Insulin-like Growth Factor-1 in a Time-Dependent Manner in Men With Obstructive Sleep Apnea: A Randomized Sham-Controlled Study. Sleep, 37(4), 733-741. [More Information]
  • Baxter, R. (2014). IGF binding proteins in cancer: mechanistic and clinical insights. Nature Reviews. Cancer, 14(5), 329-341. [More Information]
  • Martin, J., de Silva, H., Lin, Z., Scott, C., Baxter, R. (2014). Inhibition of insulin-like growth factor binding protein-3 signaling through sphingosine kinase 1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Molecular Cancer Therapeutics, 13(2), 316-328. [More Information]
  • Lin, Z., Marzec, K., Martin, J., Baxter, R. (2014). The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene, 33(1), 85-96. [More Information]
  • Greenall, S., Bentley, J., Pearce, L., Scoble, J., Sparrow, L., Bartone, N., Xiao, X., Baxter, R., Cosgrove, L., Adams, T. (2013). Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer. Journal of Biological Chemistry, 288(1), 59-68. [More Information]
  • Soon, P., Kim, E., Pon, C., Gill, A., Moore, K., Spillane, A., Benn, D., Baxter, R. (2013). Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocrine-Related Cancer, 20(1), 1-12. [More Information]
  • Grkovic, S., O'Reilly, V., Han, S., Hong, M., Baxter, R., Firth, S. (2013). IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene, 32(19), 2412-2420. [More Information]
  • Baxter, R. (2013). Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions. Journal of Cell Communication and Signaling, 7(3), 179-189. [More Information]
  • Schedlich, L., Yenson, V., Baxter, R. (2013). TGF-beta-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Molecular And Cellular Endocrinology, 377(1-2), 56-64. [More Information]
  • Chung, L., Shibli, S., Moore, K., Elder, E., Boyle, F., Marsh, D., Baxter, R. (2013). Tissue biomarkers of breast cancer and their association with conventional pathologic features. British Journal of Cancer, 108(2), 351-360. [More Information]
  • Leong, S., McKay, M., Christopherson, R., Baxter, R. (2012). Biomarkers of Breast Cancer Apoptosis Induced by Chemotherapy and TRAIL. Journal of Proteome Research, 11(2), 1240-1250. [More Information]
  • Chung, L., Baxter, R. (2012). Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Review of Proteomics, 9(6), 599-614. [More Information]
  • Birzniece, V., Meinhardt, U., Gibney, J., Johannsson, G., Armstrong, N., Baxter, R., Ho, K. (2012). Differential Effects of Raloxifene and Estrogen on Body Composition in Growth Hormone-Replaced Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 97(3), 1005-1012. [More Information]
  • Xue, A., Gandy, R., Chung, L., Baxter, R., Smith, R. (2012). Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology, 12(2), 124-129. [More Information]
  • Mertens, I., Baxter, R., Marsh, D. (2012). Gonadotropin signalling in epithelial ovarian cancer. Cancer Letters, 324(2), 152-159. [More Information]
  • Gribben, L., Baxter, R., Marsh, D. (2012). Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Letters, 317(1), 41-48. [More Information]
  • de Silva, H., Firth, S., Twigg, S., Baxter, R. (2012). Interaction Between IGF Binding Protein-3 and TGFb in in the Regulation of Adipocyte Differentiation. Endocrinology, 153(10), 4799-4807. [More Information]
  • Leong, S., Nunez, A., Lin, Z., Crossett, B., Christopherson, R., Baxter, R. (2012). iTRAQ-Based Proteomic Profiling of Breast Cancer Cell Response to Doxorubicin and TRAIL. Journal of Proteome Research, 11(7), 3561-3572. [More Information]
  • Jarajapu, Y., Cai, J., Yan, Y., Calzi, S., Kielczewski, J., Hu, P., Shaw, L., Firth, S., Chan-Ling, T., Boulton, M., Baxter, R., et al (2012). Protection of Blood Retinal Barrier and Systemic Vasculature by Insulin-Like Growth Factor Binding Protein-3. PloS One, 7(7), 1-16. [More Information]
  • Xue, A., Chang, J., Chung, L., Samra, J., Hugh, T., Gill, A., Butterini, G., Baxter, R., Smith, R. (2012). Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. British Journal of Cancer, 107(11), 1883-1891. [More Information]
  • Firth, S., Yan, X., Baxter, R. (2011). D440N Mutation in the Acid-Labile Subunit of Insulin-Like Growth Factor Complexes Inhibits Secretion and Complex Formation. Molecular Endocrinology, 25(2), 307-314. [More Information]
  • Gielen, M., Mesotten, D., Brugts, M., Coopmans, W., Van Herck, E., Vanhorebeek, L., Baxter, R., Lamberts, S., Janssen, J., Van den Berghe, G. (2011). Effect of Intensive Insulin Therapy on the Somatotropic Axis of Critically Ill Children. Journal of Clinical Endocrinology and Metabolism, 96(8), 2558-2566. [More Information]
  • Kielczewski, J., Calzi, S., Shaw, L., Cai, J., Qi, X., Ruan, Q., Wu, L., Liu, L., Hu, P., Chan-Ling, T., Firth, S., Baxter, R., et al (2011). Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Investigative Ophthalmology and Visual Science, 52(11), 8278-8286. [More Information]
  • Martin, J., Baxter, R. (2011). Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors, 29(6), 235-244. [More Information]
  • Xue, A., Scarlett, C., Chung, L., Butturini, G., Scarpa, A., Gandy, R., Wilson, S., Baxter, R., Smith, R. (2010). Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. British Journal of Cancer, 103(3), 391-400. [More Information]
  • Clifton, V., Hodyl, N., Murphy, V., Giles, W., Baxter, R., Smith, R. (2010). Effect of maternal asthma, inhaled glucocorticoids and cigarette use during pregnancy on the newborn insulin-like growth factor axis. Growth Hormone and IGF Research, 20(1), 39-48. [More Information]
  • Mertens, I., Bolitho (nee Donald), C., Baxter, R., Marsh, D. (2010). Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocrine-Related Cancer, 17(2), 335-349. [More Information]
  • Yan, X., Baxter, R., Firth, S. (2010). Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. Journal of Clinical Endocrinology and Metabolism, 95(3), 1412-1420. [More Information]
  • Birzniece, V., Meinhardt, U., Gibney, J., Johannsson, G., Baxter, R., Seibel, M., Ho, K. (2010). Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 95(5), 2099-2106. [More Information]
  • Bolitho (nee Donald), C., Hahn, M., Baxter, R., Marsh, D. (2010). The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer, 17(4), 929-940. [More Information]
  • Westwood, M., Maqsood, A., Solomon, M., Whatmore, A., Davis, J., Baxter, R., Gevers, E., Robinson, I., Clayton, P. (2010). The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat. American Journal of Physiology: Endocrinology and Metabolism, 298, E467-E476. [More Information]
  • Baxter, R., Twigg, S. (2009). Actions of IGF binding proteins and related proteins in adipose tissue. Trends in Endocrinology and Metabolism, 20(10), 499-505. [More Information]
  • Yan, X., Payet, L., Baxter, R., Firth, S. (2009). Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology, 150(11), 4968-4976. [More Information]
  • Chung, L., Baxter, R. (2009). Detection of growth hormone responsive proteins using SELDI-TOF mass spectrometry. Growth Hormone and IGF Research, 19(4), 383-387. [More Information]
  • O'Han, M., Baxter, R., Schedlich, L. (2009). Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors, 27(6), 394-408. [More Information]
  • Chan, S., Schedlich, L., Twigg, S., Baxter, R. (2009). Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. American Journal of Physiology: Endocrinology and Metabolism, 296(4), E654-E663. [More Information]
  • Martin, J., Lin, Z., McGowan, E., Baxter, R. (2009). Potentiation of growth factor signaling by insulin-like growth factor binding protein-3 in breast epithelial cells requires sphingosine kinase activity. Journal of Biological Chemistry, 284(38), 25542-25552. [More Information]
  • Chung, L., Nelson, A., Ho, K., Baxter, R. (2009). Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes. Journal of Clinical Endocrinology and Metabolism, 94(8), 3038-3043. [More Information]
  • Chuang, S., Patton, K., Schafernak, K., Papavero, V., Lin, F., Baxter, R., Teh, B., Yang, X. (2008). Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. The Journal of Urology, 179(2), 445-449. [More Information]
  • Nelson, A., Meinhardt, U., Hansen, J., Walker, I., Stone, G., Howe, C., Leung, K., Seibel, M., Baxter, R., Handelsman, D., et al (2008). Pharmacodynamics of Growth Hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. Journal of Clinical Endocrinology and Metabolism, 93(6), 2213-2222. [More Information]
  • Gosby, A., Stanton, L., Maloney, C., Thompson, M., Briody, J., Baxter, R., Bryson, J., Denyer, G., Caterson, I. (2008). Postnatal nutrition alters body composition in adult offspring exposed to maternal protein restriction. British Journal of Nutrition, 101(2), 1878-1884. [More Information]
  • Marsh, D., Trahair, T., Martin, J., Chee, W., Walker, J., Kirk, E., Baxter, R., Marshall, G. (2008). Rapamycin treatment for a child with germline PTEN mutation. Nature Clinical Practice Oncology, 5(6), 357-361. [More Information]
  • Nguyen, T., Nelson, A., Howe, C., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2008). Within-Subject Variability and Analytic Imprecision of Insulinlike Growth Factor Axis and Collagen Markers: Implications for Clinical Diagnosis and Doping Tests. Clinical Chemistry (Washington, DC), 54(8), 1268-1276. [More Information]
  • Scarlett, C., Samra, J., Xue, A., Baxter, R., Smith, R. (2007). Classification of pancreatic cystic lesions using seldi-tof mass spectrometry. ANZ Journal of Surgery, 77(8), 648-653. [More Information]
  • Martin, J., Baxter, R. (2007). Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology, 148(5), 2532-2541. [More Information]
  • Baxter, R., Smith, R., Scarlett, C., Xue, A., Butturini, G., Scarpa, A. (2007). Hp07 proteomic identification of serum markers of pancreatic adenocarcinoma using seldi-tof ms. ANZ Journal of Surgery, 77(suppl.1), A41-A41. [More Information]
  • Schedlich, L., Muthukaruppan, A., O'Han, M., Baxter, R. (2007). Insulin-Like Growth Factor Binding Protein-5 Interacts with the Vitamin D Receptor and Modulates the Vitamin D Response in Osteoblasts. Molecular Endocrinology, 21(10), 2378-2390. [More Information]
  • Schedlich, L., Graham, L., O'Han, M., Muthukaruppan, A., Yan, X., Firth, S., Baxter, R. (2007). Molecular basis of the interaction between IGFBP-3 and retinoid X receptor: Role in modulation of RAR-signaling. Archives of Biochemistry and Biophysics, 465(2), 359-369. [More Information]
  • Leong, S., Christopherson, R., Baxter, R. (2007). Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cellular Physiology and Biochemistry, 20(5), 579-590. [More Information]
  • Graham, M., Kilby, D., Firth, S., Robinson, P., Baxter, R. (2007). The in vivo phosphorylation and glycosylation of human insulin-like growth factor binding protein-5. Molecular and Cellular Proteomics, 6(8), 1392-1405. [More Information]
  • Nelson, A., Howe, C., Nguyen, T., Leung, K., Trout, G., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2006). Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. Journal of Clinical Endocrinology and Metabolism, 91(11), 4424-4432. [More Information]
  • Baxter, R., Chung, L., Clifford, D., Buckley, M. (2006). Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. Journal of Clinical Endocrinology and Metabolism, 91(2), 671-677. [More Information]
  • Santer, F., Bacher, N., Moser, B., Morandell, D., Ressler, S., Firth, S., Spoden, G., Sergi, C., Baxter, R., Jansen-Durr, P., et al (2006). Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Research, 66(6), 3024-3033. [More Information]
  • Marsh, D., Baxter, R., Moscova, M. (2006). Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Research, 66(3), 1376-1383. [More Information]
  • Scarlett, C., Smith, R., Saxby, A., Nielsen, A., Samra, J., Wilson, S., Baxter, R. (2006). Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology, 130(6), 1670-1678. [More Information]
  • Bell, C., Samra, J., Hugh, T., Baxter, R., Smith, R., Saxby, A., Nielsen, A., Scarlett, C. (2006). Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology, 44(3), 658-666. [More Information]
  • Yan, X., Baxter, R., Perbal, B., Firth, S. (2006). The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology, 147(11), 5268-5274. [More Information]
  • Takahashi, M., Papavero, V., Yuhas, J., Kort, E., Kanayama, H., Kagawa, S., Baxter, R., Yang, X., Gray, S., Teh, B. (2005). Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. International Journal of Oncology, 26(4), 923-31. [More Information]
  • Sevette, A., Smith, R., Aslani, A., Kee, A., Hansen, R., Barratt, S., Baxter, R. (2005). Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial. Clinical Nutrition, 24(6), 943-955. [More Information]
  • Butt, A., Dickson, K., Jambazov, S., Baxter, R. (2005). Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology, 146(7), 3113-3122. [More Information]
  • Nelson, A., Howe, C., Nguyen, T., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2005). Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes. Clinical Endocrinology, 63(3), 305-309. [More Information]
  • Chan, S., Twigg, S., Firth, S., Baxter, R. (2005). Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. Journal of Clinical Endocrinology and Metabolism, 90(12), 6588-6595. [More Information]
  • Brand-Miller, J., Liu, V., Petocz, P., Baxter, R. (2005). The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects. American Journal of Clinical Nutrition, 82(2), 350-354. [More Information]
  • Healy, M., Dall, R., Gibney, J., Bassett, E., Ehrnborg, C., Pentecost, C., Rosen, T., Cittadini, A., Baxter, R., Sönksen, P. (2005). Toward the Development of a Test for Growth Hormone (GH) Abuse: A Study of Extreme Physiological Ranges of GH-Dependent Markers in 813 Elite Athletes in the Postcompetition Setting. Journal of Clinical Endocrinology and Metabolism, 90(2), 641-649.
  • Scarlett, C., O'Leary, M., Lee, A., Nielsen, A., Sevette, A., Baxter, R., Smith, R. (2004). A Study Of Parenteral Versus Enteral Nutrition Following Caecal Ligation And Puncture In The Rat: Influence On Survival And Tissue Protein Turnover. Clinical Nutrition, 23(5), 1135-1145. [More Information]
  • Butt, A., Martin, J., Dickson, K., McDougall, F., Firth, S., Baxter, R. (2004). Insulin-Like Growth Factor Binding Protein-3 Expression Is Associated With Growth Stimulation Of T47D Human Breast Cancer Cells: The Role Of Altered Epidermal Growth Factor Signaling. Journal of Clinical Endocrinology and Metabolism, 89(4), 1950-1956.
  • Schedlich, L., O'Han, M., Leong, G., Baxter, R. (2004). Insulin-Like Growth Factor Binding Protein-3 Prevents Retinoid Receptor Heterodimerization: Implications For Retinoic Acid-Sensitivity In Human Breast Cancer Cells. Biochemical and Biophysical Research Communications, 314(1), 83-88. [More Information]
  • Mesotten, D., Wouters, P., Peeters, R., Hardman, K., Holly, J., Baxter, R., Van den Berghe, G. (2004). Regulation Of The Somatotropic Axis By Intensive Insulin Therapy During Protracted Critical Illness. Journal of Clinical Endocrinology and Metabolism, 89(7), 3105-3113.
  • Yan, X., Forbes, B., McNeil, K., Baxter, R., Firth, S. (2004). Role Of N- And C-Terminal Residues Of Insulin-Like Growth Factor (IGF)-Binding Protein-3 In Regulating IGF Complex Formation And Receptor Activation. Journal of Biological Chemistry, 279(51), 53232-53240.
  • Payet, L., Firth, S., Baxter, R. (2004). The Role Of The Acid-Labile Subunit In Regulating Insulin-Like Growth Factor Transport Across Human Umbilical Vein Endothelial Cell Monolayers. Journal of Clinical Endocrinology and Metabolism, 89(5), 2382-2389.
  • Payet, L., Wang, X., Baxter, R., Firth, S. (2003). Amino-and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology, 144(7), 2797-2806.
  • Mesotten, D., Van den Berghe, G., Liddle, C., Coulter, S., McDougall, F., Baxter, R., Delhanty, P. (2003). Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology, 144(9), 4008-4017.
  • Srinivasan, S., Baxter, R., Waters, M., Rowland, J., Verge, C. (2003). Hyperinsulinism and overgrowth without obesity. Archives of Disease in Childhood, 88(4), 332-334.
  • Martin, J., Weenink, S., Baxter, R. (2003). Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Journal of Biological Chemistry, 278(5), 2969-2976.
  • Butt, A., Dickson, K., McDougall, F., Baxter, R. (2003). Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. Journal of Biological Chemistry, 278(32), 29676-29685.
  • Gunton, J., Delhanty, P., Takahashi, S., Baxter, R. (2003). Metaformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. Journal of Clinical Endocrinology and Metabolism, 88(3), 1323-1332.
  • Schedlich, L., Nilsen, T., John, A., Jans, D., Baxter, R. (2003). Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology, 144(5), 1984-1993.
  • Frystyk, J., Nyholm, B., Skjærbæk, C., Baxter, R., Schmitz, O., Orskov, H. (2003). The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects. Clinical Endocrinology, 58(6), 777-784.
  • Ehrnborg, C., Lange, K., Dall, R., Christiansen, J., Lundberg, P., Baxter, R., Boroujerdi, M., Bengtsson, B., Healey, M., Pentecost, C., et al (2003). The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercies test. Journal of Clinical Endocrinology and Metabolism, 88(1), 394-401.
  • Kong, S., Baxter, R., Delhanty, P. (2002). Age-Dependent Regulation of the Acid-Labile Subunit in Response to Fasting-Refeeding in Rats. Endocrinology, 143(12), 4505-4512.
  • Firth, S., Baxter, R. (2002). Cellular Actions of the Insulin-like Growth Factor Binding Proteins. Endocrine Reviews, 23(6), 824-854.
  • Delhanty, P., Mesotten, D., McDougall, F., Baxter, R. (2002). Growth Hormone Rapidly Induces Resistin Gene Expression in White Adipose Tissue of Spontaneous Dwarf (SDR) Rats. Endocrinology, 143(6), 2445-2448.
  • Butt, A., Fraley, K., Firth, S., Baxter, R. (2002). IGF-Binding Protein-3-Induced Growth Inhibition and Apoptosis Do Not Require Cell Surface Binding and Nuclear Translocation in Human Breast Cancer Cells. Endocrinology, 143(7), 2693-2699.
  • Firth, S., McDougall, F., McLachlan, A., Baxter, R. (2002). Impaired Blockade of Insulin-Like Growth Factor I (IGF-I)-Induced Hypoglycemia by IGF Binding Protein-3 Analog with Reduced Ternary Complex-Forming Ability. Endocrinology, 143(5), 1669-1676.
  • Kodama, Y., Baxter, R., Martin, J. (2002). Insulin-like Growth Factor-I Inhibits Cell Growth in the A549 Non-Small Lung Cancer Cell Line. American Journal of Respiratory Cell and Molecular Biology, 27(3), 336-344.
  • Baxter, R., Meka, S., Firth, S. (2002). Molecular Distribution of IGF Binding Protein-5 in Human Serum. Journal of Clinical Endocrinology and Metabolism, 87(1), 271-276.
  • Mesotten, D., Delhanty, P., Vanderhoydonc, F., Hardman,, K., Weekers, F., Baxter, R., Van den Berghe, G. (2002). Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness. Journal of Clinical Endocrinology and Metabolism, 87(12), 5516-5523.
  • Kong, S., Firth, S., Baxter, R., Delhanty, P. (2002). Regulation of the acid-labile subunit in sustained endotoxemia. American Journal of Physiology: Endocrinology and Metabolism, , 692-701.
  • Donaghy, A., Delhanty, P., Ho, K., Baxter, R., Williams, R. (2002). Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. Journal of Hepatology, 36(6), 751-758.
  • Fanayan, S., Firth, S., Baxter, R. (2002). Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells: Relationship to transforming growth factor -β1 signaling. Journal of Biological Chemistry, 277(9), 7255-7261.
  • Van den Berghe, G., Baxter, R., Weekers, F., Wouters, P., Bowers, C., Iranmanesh, A., Veldhuis, J., Bouillon, R. (2002). The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical Endocrinology, 56(5), 655-669.
  • Delhanty, P., Scott, C., Baxter, R., Babu,, S. (2001). Acid-labile subunit regulation during the early stages of liver regeneration: implications for glucoregulation. American Journal of Physiology: Endocrinology and Metabolism, 280.
  • Baxter, R. (2001). Changes in the IGF-IGFBP axis in critical illness. Best Practice and Research: Clinical Endocrinology and Metabolism, 15, 421-434.
  • Baxter, R., Van, D., Weekers, F., Wouters, P., Iranmanesh, A., Bouillon,, R., Veldhuis, J. (2001). Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. Journal of Clinical Endocrinology and Metabolism, 86, 3217-3226.
  • Baxter, R., Ranke, M., Feldt-Rasmussen, U., Bang,, P., Camacho-Hubner, C., Clemmons,, D., Juul, A., Orskov, H., Strasburger, C. (2001). How should insulin-like growth factor I be measured? Hormone Research, 55 (suppl), 106-109.
  • Baxter, R. (2001). Inhibition of the insulin-like growth factor (IGF)-IGF-binding protein interaction. Hormone Research, 55 (suppl), 68-72.
  • Firth, S., Baxter, R., Galanis, M., Bond,, J., Nathanielsz, A., Kortt, A., Hudson,, P. (2001). Ligand-binding characteristics of recombinant amino-and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. Journal of Endocrinology, 169, 123-133.
  • Firth, S., Baxter, R., Clemmons,, D. (2001). Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding. Endocrinology, 142(5), 2147-2150.
  • Sevette, A., Baxter, R., Smith, R., Kee,, A., Carlsson, A. (2001). Parenteral nutrition with lipid or glucose suppresses liver growth and response to GH in adolescent male rats. American Journal of Physiology: Endocrinology and Metabolism, 281.
  • Baxter, R. (2001). Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology, 54, 145-148.
  • Baxter, R. (2001). What is the significance of IGF-binding protein-3 proteolysis in the circulation? Journal of Clinical Endocrinology and Metabolism, 86(10), 5087-5088.

Conferences

  • Moscova, M., Marsh, D., Baxter, R. (2005). Identification of Cytokines regulated by phosphatidylinositol-3 kinase in ovarian cancer. AACR-NCI-EORTC International Conference 2005, United States: American Association for Cancer Research.

2014

  • Hoyos, C., Killick, R., Keenan, D., Baxter, R., Veldhuis, J., Liu, P. (2014). Continuous Positive Airway Pressure Increases Pulsatile Growth Hormone Secretion and Circulating Insulin-like Growth Factor-1 in a Time-Dependent Manner in Men With Obstructive Sleep Apnea: A Randomized Sham-Controlled Study. Sleep, 37(4), 733-741. [More Information]
  • Baxter, R. (2014). IGF binding proteins in cancer: mechanistic and clinical insights. Nature Reviews. Cancer, 14(5), 329-341. [More Information]
  • Martin, J., de Silva, H., Lin, Z., Scott, C., Baxter, R. (2014). Inhibition of insulin-like growth factor binding protein-3 signaling through sphingosine kinase 1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Molecular Cancer Therapeutics, 13(2), 316-328. [More Information]
  • Lin, Z., Marzec, K., Martin, J., Baxter, R. (2014). The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene, 33(1), 85-96. [More Information]

2013

  • Greenall, S., Bentley, J., Pearce, L., Scoble, J., Sparrow, L., Bartone, N., Xiao, X., Baxter, R., Cosgrove, L., Adams, T. (2013). Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer. Journal of Biological Chemistry, 288(1), 59-68. [More Information]
  • Soon, P., Kim, E., Pon, C., Gill, A., Moore, K., Spillane, A., Benn, D., Baxter, R. (2013). Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocrine-Related Cancer, 20(1), 1-12. [More Information]
  • Grkovic, S., O'Reilly, V., Han, S., Hong, M., Baxter, R., Firth, S. (2013). IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene, 32(19), 2412-2420. [More Information]
  • Baxter, R. (2013). Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions. Journal of Cell Communication and Signaling, 7(3), 179-189. [More Information]
  • Schedlich, L., Yenson, V., Baxter, R. (2013). TGF-beta-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Molecular And Cellular Endocrinology, 377(1-2), 56-64. [More Information]
  • Chung, L., Shibli, S., Moore, K., Elder, E., Boyle, F., Marsh, D., Baxter, R. (2013). Tissue biomarkers of breast cancer and their association with conventional pathologic features. British Journal of Cancer, 108(2), 351-360. [More Information]

2012

  • Leong, S., McKay, M., Christopherson, R., Baxter, R. (2012). Biomarkers of Breast Cancer Apoptosis Induced by Chemotherapy and TRAIL. Journal of Proteome Research, 11(2), 1240-1250. [More Information]
  • Chung, L., Baxter, R. (2012). Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Review of Proteomics, 9(6), 599-614. [More Information]
  • Birzniece, V., Meinhardt, U., Gibney, J., Johannsson, G., Armstrong, N., Baxter, R., Ho, K. (2012). Differential Effects of Raloxifene and Estrogen on Body Composition in Growth Hormone-Replaced Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 97(3), 1005-1012. [More Information]
  • Xue, A., Gandy, R., Chung, L., Baxter, R., Smith, R. (2012). Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology, 12(2), 124-129. [More Information]
  • Mertens, I., Baxter, R., Marsh, D. (2012). Gonadotropin signalling in epithelial ovarian cancer. Cancer Letters, 324(2), 152-159. [More Information]
  • Gribben, L., Baxter, R., Marsh, D. (2012). Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Letters, 317(1), 41-48. [More Information]
  • de Silva, H., Firth, S., Twigg, S., Baxter, R. (2012). Interaction Between IGF Binding Protein-3 and TGFb in in the Regulation of Adipocyte Differentiation. Endocrinology, 153(10), 4799-4807. [More Information]
  • Leong, S., Nunez, A., Lin, Z., Crossett, B., Christopherson, R., Baxter, R. (2012). iTRAQ-Based Proteomic Profiling of Breast Cancer Cell Response to Doxorubicin and TRAIL. Journal of Proteome Research, 11(7), 3561-3572. [More Information]
  • Jarajapu, Y., Cai, J., Yan, Y., Calzi, S., Kielczewski, J., Hu, P., Shaw, L., Firth, S., Chan-Ling, T., Boulton, M., Baxter, R., et al (2012). Protection of Blood Retinal Barrier and Systemic Vasculature by Insulin-Like Growth Factor Binding Protein-3. PloS One, 7(7), 1-16. [More Information]
  • Xue, A., Chang, J., Chung, L., Samra, J., Hugh, T., Gill, A., Butterini, G., Baxter, R., Smith, R. (2012). Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma. British Journal of Cancer, 107(11), 1883-1891. [More Information]

2011

  • Firth, S., Yan, X., Baxter, R. (2011). D440N Mutation in the Acid-Labile Subunit of Insulin-Like Growth Factor Complexes Inhibits Secretion and Complex Formation. Molecular Endocrinology, 25(2), 307-314. [More Information]
  • Gielen, M., Mesotten, D., Brugts, M., Coopmans, W., Van Herck, E., Vanhorebeek, L., Baxter, R., Lamberts, S., Janssen, J., Van den Berghe, G. (2011). Effect of Intensive Insulin Therapy on the Somatotropic Axis of Critically Ill Children. Journal of Clinical Endocrinology and Metabolism, 96(8), 2558-2566. [More Information]
  • Kielczewski, J., Calzi, S., Shaw, L., Cai, J., Qi, X., Ruan, Q., Wu, L., Liu, L., Hu, P., Chan-Ling, T., Firth, S., Baxter, R., et al (2011). Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Investigative Ophthalmology and Visual Science, 52(11), 8278-8286. [More Information]
  • Martin, J., Baxter, R. (2011). Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors, 29(6), 235-244. [More Information]

2010

  • Xue, A., Scarlett, C., Chung, L., Butturini, G., Scarpa, A., Gandy, R., Wilson, S., Baxter, R., Smith, R. (2010). Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. British Journal of Cancer, 103(3), 391-400. [More Information]
  • Clifton, V., Hodyl, N., Murphy, V., Giles, W., Baxter, R., Smith, R. (2010). Effect of maternal asthma, inhaled glucocorticoids and cigarette use during pregnancy on the newborn insulin-like growth factor axis. Growth Hormone and IGF Research, 20(1), 39-48. [More Information]
  • Mertens, I., Bolitho (nee Donald), C., Baxter, R., Marsh, D. (2010). Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocrine-Related Cancer, 17(2), 335-349. [More Information]
  • Yan, X., Baxter, R., Firth, S. (2010). Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. Journal of Clinical Endocrinology and Metabolism, 95(3), 1412-1420. [More Information]
  • Birzniece, V., Meinhardt, U., Gibney, J., Johannsson, G., Baxter, R., Seibel, M., Ho, K. (2010). Modulatory Effect of Raloxifene and Estrogen on the Metabolic Action of Growth Hormone in Hypopituitary Women. Journal of Clinical Endocrinology and Metabolism, 95(5), 2099-2106. [More Information]
  • Bolitho (nee Donald), C., Hahn, M., Baxter, R., Marsh, D. (2010). The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer, 17(4), 929-940. [More Information]
  • Westwood, M., Maqsood, A., Solomon, M., Whatmore, A., Davis, J., Baxter, R., Gevers, E., Robinson, I., Clayton, P. (2010). The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat. American Journal of Physiology: Endocrinology and Metabolism, 298, E467-E476. [More Information]

2009

  • Baxter, R., Twigg, S. (2009). Actions of IGF binding proteins and related proteins in adipose tissue. Trends in Endocrinology and Metabolism, 20(10), 499-505. [More Information]
  • Yan, X., Payet, L., Baxter, R., Firth, S. (2009). Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology, 150(11), 4968-4976. [More Information]
  • Chung, L., Baxter, R. (2009). Detection of growth hormone responsive proteins using SELDI-TOF mass spectrometry. Growth Hormone and IGF Research, 19(4), 383-387. [More Information]
  • O'Han, M., Baxter, R., Schedlich, L. (2009). Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors, 27(6), 394-408. [More Information]
  • Chan, S., Schedlich, L., Twigg, S., Baxter, R. (2009). Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. American Journal of Physiology: Endocrinology and Metabolism, 296(4), E654-E663. [More Information]
  • Martin, J., Lin, Z., McGowan, E., Baxter, R. (2009). Potentiation of growth factor signaling by insulin-like growth factor binding protein-3 in breast epithelial cells requires sphingosine kinase activity. Journal of Biological Chemistry, 284(38), 25542-25552. [More Information]
  • Chung, L., Nelson, A., Ho, K., Baxter, R. (2009). Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes. Journal of Clinical Endocrinology and Metabolism, 94(8), 3038-3043. [More Information]

2008

  • Baxter, R. (2008). Insulin-like Growth Factors and Tumor Hypoglycemia. In Ian D. Hay, John A. H. Wass (Eds.), Clinical Endocrine Oncology - 2nd Edition, (pp. 576-581). United Kingdom: Blackwell Publishers.
  • Chuang, S., Patton, K., Schafernak, K., Papavero, V., Lin, F., Baxter, R., Teh, B., Yang, X. (2008). Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. The Journal of Urology, 179(2), 445-449. [More Information]
  • Nelson, A., Meinhardt, U., Hansen, J., Walker, I., Stone, G., Howe, C., Leung, K., Seibel, M., Baxter, R., Handelsman, D., et al (2008). Pharmacodynamics of Growth Hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. Journal of Clinical Endocrinology and Metabolism, 93(6), 2213-2222. [More Information]
  • Gosby, A., Stanton, L., Maloney, C., Thompson, M., Briody, J., Baxter, R., Bryson, J., Denyer, G., Caterson, I. (2008). Postnatal nutrition alters body composition in adult offspring exposed to maternal protein restriction. British Journal of Nutrition, 101(2), 1878-1884. [More Information]
  • Marsh, D., Trahair, T., Martin, J., Chee, W., Walker, J., Kirk, E., Baxter, R., Marshall, G. (2008). Rapamycin treatment for a child with germline PTEN mutation. Nature Clinical Practice Oncology, 5(6), 357-361. [More Information]
  • Nguyen, T., Nelson, A., Howe, C., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2008). Within-Subject Variability and Analytic Imprecision of Insulinlike Growth Factor Axis and Collagen Markers: Implications for Clinical Diagnosis and Doping Tests. Clinical Chemistry (Washington, DC), 54(8), 1268-1276. [More Information]

2007

  • Scarlett, C., Samra, J., Xue, A., Baxter, R., Smith, R. (2007). Classification of pancreatic cystic lesions using seldi-tof mass spectrometry. ANZ Journal of Surgery, 77(8), 648-653. [More Information]
  • Martin, J., Baxter, R. (2007). Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology, 148(5), 2532-2541. [More Information]
  • Baxter, R., Smith, R., Scarlett, C., Xue, A., Butturini, G., Scarpa, A. (2007). Hp07 proteomic identification of serum markers of pancreatic adenocarcinoma using seldi-tof ms. ANZ Journal of Surgery, 77(suppl.1), A41-A41. [More Information]
  • Schedlich, L., Muthukaruppan, A., O'Han, M., Baxter, R. (2007). Insulin-Like Growth Factor Binding Protein-5 Interacts with the Vitamin D Receptor and Modulates the Vitamin D Response in Osteoblasts. Molecular Endocrinology, 21(10), 2378-2390. [More Information]
  • Schedlich, L., Graham, L., O'Han, M., Muthukaruppan, A., Yan, X., Firth, S., Baxter, R. (2007). Molecular basis of the interaction between IGFBP-3 and retinoid X receptor: Role in modulation of RAR-signaling. Archives of Biochemistry and Biophysics, 465(2), 359-369. [More Information]
  • Leong, S., Christopherson, R., Baxter, R. (2007). Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cellular Physiology and Biochemistry, 20(5), 579-590. [More Information]
  • Graham, M., Kilby, D., Firth, S., Robinson, P., Baxter, R. (2007). The in vivo phosphorylation and glycosylation of human insulin-like growth factor binding protein-5. Molecular and Cellular Proteomics, 6(8), 1392-1405. [More Information]

2006

  • Nelson, A., Howe, C., Nguyen, T., Leung, K., Trout, G., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2006). Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. Journal of Clinical Endocrinology and Metabolism, 91(11), 4424-4432. [More Information]
  • Baxter, R., Chung, L., Clifford, D., Buckley, M. (2006). Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. Journal of Clinical Endocrinology and Metabolism, 91(2), 671-677. [More Information]
  • Santer, F., Bacher, N., Moser, B., Morandell, D., Ressler, S., Firth, S., Spoden, G., Sergi, C., Baxter, R., Jansen-Durr, P., et al (2006). Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Research, 66(6), 3024-3033. [More Information]
  • Marsh, D., Baxter, R., Moscova, M. (2006). Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Research, 66(3), 1376-1383. [More Information]
  • Scarlett, C., Smith, R., Saxby, A., Nielsen, A., Samra, J., Wilson, S., Baxter, R. (2006). Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology, 130(6), 1670-1678. [More Information]
  • Bell, C., Samra, J., Hugh, T., Baxter, R., Smith, R., Saxby, A., Nielsen, A., Scarlett, C. (2006). Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology, 44(3), 658-666. [More Information]
  • Yan, X., Baxter, R., Perbal, B., Firth, S. (2006). The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology, 147(11), 5268-5274. [More Information]

2005

  • Takahashi, M., Papavero, V., Yuhas, J., Kort, E., Kanayama, H., Kagawa, S., Baxter, R., Yang, X., Gray, S., Teh, B. (2005). Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. International Journal of Oncology, 26(4), 923-31. [More Information]
  • Sevette, A., Smith, R., Aslani, A., Kee, A., Hansen, R., Barratt, S., Baxter, R. (2005). Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial. Clinical Nutrition, 24(6), 943-955. [More Information]
  • Butt, A., Dickson, K., Jambazov, S., Baxter, R. (2005). Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology, 146(7), 3113-3122. [More Information]
  • Nelson, A., Howe, C., Nguyen, T., Seibel, M., Baxter, R., Handelsman, D., Kazlauskas, R., Ho, K. (2005). Erythropoietin administration does not influence the GH-IGF axis or makers of bone turnover in recreational athletes. Clinical Endocrinology, 63(3), 305-309. [More Information]
  • Moscova, M., Marsh, D., Baxter, R. (2005). Identification of Cytokines regulated by phosphatidylinositol-3 kinase in ovarian cancer. AACR-NCI-EORTC International Conference 2005, United States: American Association for Cancer Research.
  • Chan, S., Twigg, S., Firth, S., Baxter, R. (2005). Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. Journal of Clinical Endocrinology and Metabolism, 90(12), 6588-6595. [More Information]
  • Brand-Miller, J., Liu, V., Petocz, P., Baxter, R. (2005). The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects. American Journal of Clinical Nutrition, 82(2), 350-354. [More Information]
  • Healy, M., Dall, R., Gibney, J., Bassett, E., Ehrnborg, C., Pentecost, C., Rosen, T., Cittadini, A., Baxter, R., Sönksen, P. (2005). Toward the Development of a Test for Growth Hormone (GH) Abuse: A Study of Extreme Physiological Ranges of GH-Dependent Markers in 813 Elite Athletes in the Postcompetition Setting. Journal of Clinical Endocrinology and Metabolism, 90(2), 641-649.

2004

  • Scarlett, C., O'Leary, M., Lee, A., Nielsen, A., Sevette, A., Baxter, R., Smith, R. (2004). A Study Of Parenteral Versus Enteral Nutrition Following Caecal Ligation And Puncture In The Rat: Influence On Survival And Tissue Protein Turnover. Clinical Nutrition, 23(5), 1135-1145. [More Information]
  • Butt, A., Martin, J., Dickson, K., McDougall, F., Firth, S., Baxter, R. (2004). Insulin-Like Growth Factor Binding Protein-3 Expression Is Associated With Growth Stimulation Of T47D Human Breast Cancer Cells: The Role Of Altered Epidermal Growth Factor Signaling. Journal of Clinical Endocrinology and Metabolism, 89(4), 1950-1956.
  • Schedlich, L., O'Han, M., Leong, G., Baxter, R. (2004). Insulin-Like Growth Factor Binding Protein-3 Prevents Retinoid Receptor Heterodimerization: Implications For Retinoic Acid-Sensitivity In Human Breast Cancer Cells. Biochemical and Biophysical Research Communications, 314(1), 83-88. [More Information]
  • Mesotten, D., Wouters, P., Peeters, R., Hardman, K., Holly, J., Baxter, R., Van den Berghe, G. (2004). Regulation Of The Somatotropic Axis By Intensive Insulin Therapy During Protracted Critical Illness. Journal of Clinical Endocrinology and Metabolism, 89(7), 3105-3113.
  • Yan, X., Forbes, B., McNeil, K., Baxter, R., Firth, S. (2004). Role Of N- And C-Terminal Residues Of Insulin-Like Growth Factor (IGF)-Binding Protein-3 In Regulating IGF Complex Formation And Receptor Activation. Journal of Biological Chemistry, 279(51), 53232-53240.
  • Payet, L., Firth, S., Baxter, R. (2004). The Role Of The Acid-Labile Subunit In Regulating Insulin-Like Growth Factor Transport Across Human Umbilical Vein Endothelial Cell Monolayers. Journal of Clinical Endocrinology and Metabolism, 89(5), 2382-2389.

2003

  • Payet, L., Wang, X., Baxter, R., Firth, S. (2003). Amino-and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology, 144(7), 2797-2806.
  • Baxter, R., Fanayan, S. (2003). Functional relationships between transforming growth factor-beta and the insulin-like growth factor binding proteins. In Leroith, Zimkeller, Baxter (Eds.), Insulin-Like Growth Factors, (pp. 281-293). New York: Springer.
  • Mesotten, D., Van den Berghe, G., Liddle, C., Coulter, S., McDougall, F., Baxter, R., Delhanty, P. (2003). Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology, 144(9), 4008-4017.
  • Srinivasan, S., Baxter, R., Waters, M., Rowland, J., Verge, C. (2003). Hyperinsulinism and overgrowth without obesity. Archives of Disease in Childhood, 88(4), 332-334.
  • LeRoith, D., Zumkeller, W., Baxter, R. (2003). Insulin-like Growth Factor Receptor Signalling. United States: Springer.
  • Martin, J., Weenink, S., Baxter, R. (2003). Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Journal of Biological Chemistry, 278(5), 2969-2976.
  • Butt, A., Dickson, K., McDougall, F., Baxter, R. (2003). Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. Journal of Biological Chemistry, 278(32), 29676-29685.
  • Gunton, J., Delhanty, P., Takahashi, S., Baxter, R. (2003). Metaformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. Journal of Clinical Endocrinology and Metabolism, 88(3), 1323-1332.
  • Schedlich, L., Nilsen, T., John, A., Jans, D., Baxter, R. (2003). Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology, 144(5), 1984-1993.
  • Frystyk, J., Nyholm, B., Skjærbæk, C., Baxter, R., Schmitz, O., Orskov, H. (2003). The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects. Clinical Endocrinology, 58(6), 777-784.
  • Ehrnborg, C., Lange, K., Dall, R., Christiansen, J., Lundberg, P., Baxter, R., Boroujerdi, M., Bengtsson, B., Healey, M., Pentecost, C., et al (2003). The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercies test. Journal of Clinical Endocrinology and Metabolism, 88(1), 394-401.

2002

  • Kong, S., Baxter, R., Delhanty, P. (2002). Age-Dependent Regulation of the Acid-Labile Subunit in Response to Fasting-Refeeding in Rats. Endocrinology, 143(12), 4505-4512.
  • Firth, S., Baxter, R. (2002). Cellular Actions of the Insulin-like Growth Factor Binding Proteins. Endocrine Reviews, 23(6), 824-854.
  • Delhanty, P., Mesotten, D., McDougall, F., Baxter, R. (2002). Growth Hormone Rapidly Induces Resistin Gene Expression in White Adipose Tissue of Spontaneous Dwarf (SDR) Rats. Endocrinology, 143(6), 2445-2448.
  • Butt, A., Fraley, K., Firth, S., Baxter, R. (2002). IGF-Binding Protein-3-Induced Growth Inhibition and Apoptosis Do Not Require Cell Surface Binding and Nuclear Translocation in Human Breast Cancer Cells. Endocrinology, 143(7), 2693-2699.
  • Firth, S., McDougall, F., McLachlan, A., Baxter, R. (2002). Impaired Blockade of Insulin-Like Growth Factor I (IGF-I)-Induced Hypoglycemia by IGF Binding Protein-3 Analog with Reduced Ternary Complex-Forming Ability. Endocrinology, 143(5), 1669-1676.
  • Kodama, Y., Baxter, R., Martin, J. (2002). Insulin-like Growth Factor-I Inhibits Cell Growth in the A549 Non-Small Lung Cancer Cell Line. American Journal of Respiratory Cell and Molecular Biology, 27(3), 336-344.
  • Baxter, R., Meka, S., Firth, S. (2002). Molecular Distribution of IGF Binding Protein-5 in Human Serum. Journal of Clinical Endocrinology and Metabolism, 87(1), 271-276.
  • Mesotten, D., Delhanty, P., Vanderhoydonc, F., Hardman,, K., Weekers, F., Baxter, R., Van den Berghe, G. (2002). Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness. Journal of Clinical Endocrinology and Metabolism, 87(12), 5516-5523.
  • Kong, S., Firth, S., Baxter, R., Delhanty, P. (2002). Regulation of the acid-labile subunit in sustained endotoxemia. American Journal of Physiology: Endocrinology and Metabolism, , 692-701.
  • Donaghy, A., Delhanty, P., Ho, K., Baxter, R., Williams, R. (2002). Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. Journal of Hepatology, 36(6), 751-758.
  • Fanayan, S., Firth, S., Baxter, R. (2002). Signaling through the Smad Pathway by Insulin-like Growth Factor-binding Protein-3 in Breast Cancer Cells: Relationship to transforming growth factor -β1 signaling. Journal of Biological Chemistry, 277(9), 7255-7261.
  • Van den Berghe, G., Baxter, R., Weekers, F., Wouters, P., Bowers, C., Iranmanesh, A., Veldhuis, J., Bouillon, R. (2002). The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical Endocrinology, 56(5), 655-669.

2001

  • Delhanty, P., Scott, C., Baxter, R., Babu,, S. (2001). Acid-labile subunit regulation during the early stages of liver regeneration: implications for glucoregulation. American Journal of Physiology: Endocrinology and Metabolism, 280.
  • Baxter, R. (2001). Changes in the IGF-IGFBP axis in critical illness. Best Practice and Research: Clinical Endocrinology and Metabolism, 15, 421-434.
  • Baxter, R., Van, D., Weekers, F., Wouters, P., Iranmanesh, A., Bouillon,, R., Veldhuis, J. (2001). Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. Journal of Clinical Endocrinology and Metabolism, 86, 3217-3226.
  • Baxter, R., Ranke, M., Feldt-Rasmussen, U., Bang,, P., Camacho-Hubner, C., Clemmons,, D., Juul, A., Orskov, H., Strasburger, C. (2001). How should insulin-like growth factor I be measured? Hormone Research, 55 (suppl), 106-109.
  • Baxter, R. (2001). Inhibition of the insulin-like growth factor (IGF)-IGF-binding protein interaction. Hormone Research, 55 (suppl), 68-72.
  • Firth, S., Baxter, R., Galanis, M., Bond,, J., Nathanielsz, A., Kortt, A., Hudson,, P. (2001). Ligand-binding characteristics of recombinant amino-and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. Journal of Endocrinology, 169, 123-133.
  • Firth, S., Baxter, R., Clemmons,, D. (2001). Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding. Endocrinology, 142(5), 2147-2150.
  • Sevette, A., Baxter, R., Smith, R., Kee,, A., Carlsson, A. (2001). Parenteral nutrition with lipid or glucose suppresses liver growth and response to GH in adolescent male rats. American Journal of Physiology: Endocrinology and Metabolism, 281.
  • Baxter, R. (2001). Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology, 54, 145-148.
  • Baxter, R. (2001). What is the significance of IGF-binding protein-3 proteolysis in the circulation? Journal of Clinical Endocrinology and Metabolism, 86(10), 5087-5088.

To update your profile click here. For support on your academic profile contact .